Pharmacy Grand Rounds 
The GIST of It: Treatment of Gastrointestinal Stromal Tumors

• ACPE Universal Activity Number (UAN): JA0000238-0000-21-004-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST) 

Until further notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Treatment of gastrointestinal stromal tumors (GISTs) has incorporated targeted therapies since the initial approval of imatinib mesylate in 2002 for advanced or metastatic disease. Newly approved medications, including ripretinib and avapritinib, inhibit the oncogenic signaling of KIT and PDGFRA receptor tyrosine kinases differently to allow for treatment of imatinib-resistant disease. After reviewing the pathophysiology of GIST and its unique mutational landscape, the speaker will discuss the pharmacology and utilization of current therapies.

LEARNING OBJECTIVES
At the conclusion of this knowledge-based CE session, participants should be able to:

• Review pathophysiology of gastrointestinal stromal tumors
• Describe the pharmacology of medications used to treat gastrointestinal stromal tumors
• Discuss the place in therapy of new treatment options, including ripretinib and avapritinib

Session Announcement

FACULTY INFORMATION

Mikhaila L. Rice, PharmD, BCPS
PGY2 Oncology Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Mikhaila received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy in Pittsburgh, PA.  She completed a PGY1 Pharmacy Residency at Mayo Clinic Hospital – Rochester, and is currently a PGY2 Oncology Pharmacy Resident at Mayo Clinic Hospital – Rochester with practice interests in hematology, oncology, immunology, and infectious diseases.

DISCLOSURE STATEMENTS
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Mikhaila L. Rice, PharmD, BCPS
  • Declares no financial relationship(s) pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:

• Anlotinib	Pexidartinib
  Avapritinib	Ponatinib
  Cabozantinib	Regorafenib
  Crenolanib	Ripretinib
  Imatinib	Selinexor
  Ipilimumab	Spartalizumab
  Lenvantinib	Sunitinib
  Nivolumab	Temozolomide

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session. 

Members include:

• Jennifer Elmer, DNP, APRM, CCNS, FCCM
• Michael Huckabee, MPAS, PA-C, PhD
• Sarah Jane Kotval, BSW
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS
• Brenda Stellmaker